Virax Biolabs Initiates Multi-Center Clinical Study in the UK to Assess ViraxImmune™ FluoroSpot T cell Assay for Post-Acute Viral Diseases
London, UK, March 18, 2025 – Virax Biolabs Group Limited (NASDAQ: VRAX), a pioneering biotechnology company specializing in the detection of immune responses and diagnosis of viral diseases, is thrilled to announce the commencement of patient enrollment in a multicenter clinical study in the United Kingdom. This study, which carries the clinical trial registration number NCT06731179, is being conducted in collaboration with the esteemed National Health Service (NHS) and aims to evaluate the performance of ViraxImmune™ FluoroSpot T cell assay in identifying T cell dysfunction in patients suffering from post-acute infection syndromes, including long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
About the ViraxImmune™ FluoroSpot T cell Assay
The ViraxImmune™ FluoroSpot T cell assay is a cutting-edge diagnostic tool developed by Virax Biolabs. This assay is designed to detect and quantify the immune response of T cells, which are a crucial component of the adaptive immune system, against specific viral antigens. By measuring T cell responses, the assay can provide valuable insights into the immune status of patients, helping to diagnose and monitor viral infections and post-acute infection syndromes more effectively.
Study Objectives
The primary objective of this clinical study is to assess the ability of the ViraxImmune™ FluoroSpot T cell assay to detect T cell dysfunction in post-acute infection syndrome patients. Post-acute infection syndromes refer to conditions where patients continue to experience symptoms and health impairments long after the initial infection has been resolved. These conditions, such as long COVID, PTLD, and ME/CFS, can significantly impact a person’s quality of life and often lack effective diagnostic tools and treatments.
Impact on Individuals
For individuals suffering from post-acute infection syndromes like long COVID, PTLD, or ME/CFS, this clinical study represents a significant step forward in the quest for accurate diagnoses and effective treatments. If the ViraxImmune™ FluoroSpot T cell assay is found to be effective in identifying T cell dysfunction in these conditions, it could lead to earlier and more accurate diagnoses, enabling timely intervention and appropriate treatment plans to help improve patients’ lives. Furthermore, a reliable diagnostic tool could also help reduce the burden on healthcare systems by ensuring that resources are allocated more efficiently and effectively.
Impact on the World
The potential impact of this clinical study extends beyond individual patients and could significantly influence the global healthcare landscape. Accurate and early diagnoses of post-acute infection syndromes like long COVID, PTLD, and ME/CFS are crucial for public health, as these conditions can affect a large number of people, particularly in the context of ongoing and emerging infectious disease outbreaks. Moreover, the development of a reliable diagnostic tool could also pave the way for the creation of targeted therapeutic interventions, ultimately improving the overall management and treatment of these conditions.
Conclusion
Virax Biolabs’ announcement of the start of patient enrollment in the United Kingdom-based clinical study marks an essential milestone in the quest for accurate diagnoses and effective treatments for post-acute infection syndromes. The ViraxImmune™ FluoroSpot T cell assay, if successful, could significantly impact the lives of millions of individuals worldwide, as well as contribute to more efficient and effective healthcare systems. Stay tuned for updates on this groundbreaking research.
- Virax Biolabs initiates clinical study to evaluate ViraxImmune™ FluoroSpot T cell assay for post-acute infection syndromes
- Collaboration with the UK’s National Health Service to assess assay performance in long COVID, PTLD, and ME/CFS patients
- Potential for earlier and more accurate diagnoses, enabling timely intervention and effective treatment plans
- Significant impact on public health and healthcare systems worldwide
